Esperion Therapeutics (ESPR) The Citizens Life Sciences Conference 2026 summary

Financial performance and growth

• Achieved 38% year-over-year total revenue growth and 34% TRx growth, with $408 million in total revenue for 2025 and strong quarterly momentum into 2026.

• U.S. commercial access for key products is at 90% for both commercial and Medicare, with minimal payer restrictions.

• International partnerships, especially with Daiichi Sankyo in Europe and Otsuka in Japan, are driving significant patient reach and sales, with new launches in France, Canada, Australia, New Zealand, and Israel.

• Cash position is strong, ending the year with $168 million and improving, while continuing to deleverage and maintain financial flexibility.

• Confident in sustaining current growth rates, with no end in sight, and planning business well into the 2030s under the Vision 2040 strategy.

Strategic acquisition and integration

• Acquired Corstasis for $75 million upfront and up to $180 million in milestone payments, gaining a recently approved nasal loop diuretic for heart failure.

• The acquisition expands the portfolio into heart failure, complementing existing cardiometabolic offerings and leveraging commercial infrastructure.

• Integration is underway, with plans to rapidly scale commercialization and payer access, including specialty pharmacy partnerships and hospital outreach.

• Global rights to the new product open options for expansion in Europe and Asia, with future distribution or partnership models under consideration.

• The nasal spray delivery is favored for ease of use, with an auto-injector in development as an additional option.

Commercial execution and market strategy

• Focused on maximizing the Bempedoic acid franchise (NEXLIZET, NEXLETOL) and integrating ENBUMYST into the commercial team.

• Awaiting new guidelines expected to provide a significant tailwind and further validate product positioning.

• Key messages to healthcare providers emphasize risk reduction, CLEAR Outcomes data, and unique benefits for statin-intolerant patients.

• Digital marketing delivers strong ROI, especially in under-covered geographies, and will be further expanded.

• Ongoing evaluation of field force size and integration to support both legacy and new products.